We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Waters and Tecan Sign Agreement for Clinical Assay Platform

By LabMedica International staff writers
Posted on 25 Jan 2012
Waters Corporation (Milford, MA, USA) and Tecan Group (Männedorf, Switzerland) entered into an agreement to combine Tecan’s Freedom EVO liquid handling platform with Waters Acquity TQD liquid chromatograph/mass spectrometer (LC/MS/MS) to automate sample preparation. More...
This will enable better, more efficient, and higher throughput clinical LC/MS assays.

Waters will combine the technologies from both companies into a single, fully supported analytical system solution that helps laboratories increase assay throughput and efficiency, improve profitability, and reduce overall assay costs.

The firms announced the agreement at the annual meeting of the Association for Mass Spectrometry Applications to the Clinical Lab (MSACL) held on January 14-18, 2012, in San Diego (CA, USA).

"The multistep process of preparing samples for LC/MS/MS analyses remains a significant bottleneck and an opportunity for improvement in many laboratories. If there is one thing laboratory managers consistently ask for, it’s better, more automated sample preparation and analysis,” said Pat Martell, clinical marketing director, Waters Division. “Combining sample preparation and analysis in a single unified platform facilitates the entire assay process and streamlines analyses significantly. By lowering assay costs and bringing a greater consistency to test results, laboratories can offer clients a higher level of service and responsiveness."

Tecan is a global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production, and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories.

Waters innovations and laboratory solutions deliver better accuracy and precision for assays. The company is committed to helping laboratories deliver quality results with new levels of sample throughput, shortened turnaround times, and increases in sensitivity, specificity, and flexibility.

Related Links:
Waters Corporation
Tecan Group
The Association for Mass Spectrometry Applications to the Clinical Lab


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.